Mesenchymal stem/stromal cells (MSCs) exist in almost all tissues and participate in tissue
regeneration and homeostasis. In-vitro-expanded MSCs are employed as therapeutics for …

Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been
considered promising therapeutic targets for cancer therapy. These cells have self-renewal …

The multipotent mesenchymal stem/stromal cells (MSCs), initially discovered from bone
marrow in 1976, have been identified in nearly all tissues of human body now. The …

The tumor microenvironment (TME) is made up of cells and extracellular matrix (non-cellular
component), and cellular components include cancer cells and non-malignant cells such as …

Mesenchymal stem cells, also known as mesenchymal stromal cells (MSCs), exist in many
tissues and are known to actively migrate to sites of tissue injury, where they participate in …

The development of mesenchymal stem cells (MSCs) as cell-based drug delivery vectors for
numerous clinical indications, including cancer, has significant promise. However, a …

Oncolytic viruses (OVs) infect, multiply, and finally remove tumor cells selectively, causing no
damage to normal cells in the process. Because of their specific features, such as, the ability …

Increasing evidence indicates that the tumor microenvironment appears to play an
increasingly important role in cancer progression and therapeutic resistance. Several types …

Poor water solubility and low bioavailability of active pharmaceutical ingredients (APIs) are
major causes of friction in the pharmaceutical industry and represent a formidable hurdle for …

Recent pre-clinical and clinical studies have shown that stem cell-based therapies hold
tremendous promise for the treatment of human disease. Mesenchymal stem cells (MSC) …